Blocking blood supply to treat glioblastoma
Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
This study is testing a new procedure that blocks blood flow to glioblastoma tumors to see if it can help the immune system fight the cancer better in people who haven't had treatment yet.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital, Sun Yat-Sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05990556 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and efficacy of an interventional procedure aimed at blocking the blood supply from the meningeal arteries in patients diagnosed with glioblastoma. The approach is based on the hypothesis that altering the immune microenvironment can enhance the effectiveness of immune responses against the tumor. Eligible participants include those who have not undergone prior treatments for their glioblastoma, allowing for a clearer assessment of the intervention's impact. The study aims to provide insights into how manipulating blood supply can influence tumor progression and immune activation.
Who should consider this trial
Good fit: Ideal candidates are patients with a confirmed diagnosis of glioblastoma who have not received prior treatments.
Not a fit: Patients whose glioblastoma diagnosis is later confirmed to be incorrect or those with significant comorbidities affecting survival may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes for glioblastoma patients by enhancing immune responses against the tumor.
How similar studies have performed: While there is ongoing research into the immune microenvironment of glioblastoma, this specific approach of blocking meningeal blood supply is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Imaging or needle biopsy pathologically diagnosed as glioblastoma * Patients have not previously received radiotherapy, chemotherapy and other treatment modalities for intracranial lesions * There are no related contraindications such as neurovascular intervention and craniotomy Exclusion Criteria: * The patient's initial imaging diagnosis was glioblastoma, and the postoperative pathology confirmed nonglioblastoma * The patient has other underlying medical conditions that affect survival time * The patient had other underlying medical conditions that affected follow-up or quality of life assessment * Patients do not have the above exclusion criteria and refuse to participate in clinical trials after informed consent
Where this trial is running
Guangzhou, Guangdong
- the First Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Nu Zhang, Professor — First Affiliated Hospital, Sun Yat-Sen University
- Study coordinator: Nu Zhang, Professor
- Email: zhangnu2@mail.sysu.edu.cn
- Phone: 13825070717
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.